Controversies in the Early Reporting of a Clinical Trial in Early Breast Cancer

Stephen L George and Mark R. Green
Additional contact information
Stephen L George: Duke University Medical Center, Department of Biostatistics and Bioinformatics
Mark R. Green: Medical University of South Carolina, Department of Hematology/Oncology

Chapter Case 28 in Data Monitoring in Clinical Trials, 2006, pp 346-359 from Springer

Abstract: Abstract The role of adjuvant chemotherapy in the treatment of breast cancer has been the subject of intense research activity in recent years. It is now generally accepted that some types of adjuvant therapy have a positive effect on disease-free and overall survival, but the effect size appears to be modest and the optimal type of adjuvant therapy for different groups of patients remains unclear. One major study of adjuvant therapy in breast cancer patients that generated considerable interest and controversy was an intergroup trial of the value of increasing the dose of doxorubicin or adding paclitaxel (Taxol®) to standard chemotherapy. The design was a 3 x 2 factorial design (three different doses of doxorubicin with and without paclitaxel). Based on the results of the first planned interim analysis suggesting improved disease-free and overall survival in patients receiving paclitaxel, the DSMB released the results to the study team. The events and considerations leading to the decision to release the results and some of the subsequent controversies that arose in the medical community because of this decision are discussed in this paper.

Keywords: Interim Analysis; Case Study Approach; Plan Interim Analysis; United States National Cancer Institute; Sequential Paclitaxel (search for similar items in EconPapers)
Date: 2006
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-0-387-30107-5_34

Ordering information: This item can be ordered from
http://www.springer.com/9780387301075

DOI: 10.1007/0-387-30107-0_34

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().